| |
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
Today’s Big NewsNov 6, 2024 |
|
QPS has extensive expertise in the conduct of oncology clinical studies,
having successfully managed over 50 oncology studies globally.
Download the QPS Case Study to learn how QPS performed two global Phase III studies in prostate cancer patients.
|
|
| By Zoey Becker Over his first term, Donald Trump advocated for lower drug prices and pharmacy benefit manager reform. Now with the Inflation Reduction Act in play, what's to come for pharma under a Trump administration? |
|
|
|
By James Waldron Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. |
By Fraiser Kansteiner Among Novo’s semaglutide-based drugs, diabetes blockbuster Ozempic fell short of analysts' expectations during the third quarter while weight-loss med Wegovy came above a consensus estimate. |
By Conor Hale LumiThera’s Valeda system relies on photobiomodulation, or the use of different wavelengths of light to stimulate activity in the cells of the retina. |
By Nick Paul Taylor Tango Therapeutics has shuffled TNG908 off the dance floor, halting enrollment in a study of the cancer drug candidate to focus its resources on two other molecules that hit the same target. Shares in Tango fell 26% to $3.81 in premarket trading. |
By Angus Liu Novavax has inked another settlement for a past COVID-19 vaccine supply deal. The Maryland biotech has agreed to pay $123.8 million to end a COVID vaccine supply pact with the U.K. |
By James Waldron Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher—although the biotech will only be able to keep two-thirds of the windfall. |
By Conor Hale CMS delivered separate TPT payments to each developer, granting distinct category and device codes to their outpatient procedures for reducing stubbornly high blood pressure. |
By Kevin Dunleavy Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1 billion, which was a 30% increase year over year. Sales of generics also were up 10% in Europe. |
By Darren Incorvaia A team of researchers led by Stanford University and San Diego-based Boundless Bio have identified an oral small molecule that specifically targets extrachromosomal DNA in cancer cells, preventing the DNA from repairing itself. When tested in mice, the compound—named BBI-2779—shrank gastric tumors and prevented the cancer from developing resistance to another cancer drug. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy. |
|
|---|
|
|
|
Wednesday, November 13 , 2024 | 10am ET / 7am PT Join industry experts to gain insights pertinent to efficient and effective drug development. Understand and execute a risk-based critical thinking approach related to injectable drug packaging and delivery. Register now.
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
